Central Retinal Vein Occlusion: Causes and Treatment

Central retinal vein occlusion (CRVO) happens when a blood clot blocks the main vein draining blood out of the retina, causing sudden, painless vision loss in one eye. The underlying causes almost always trace back to conditions that damage blood vessels or slow blood flow, with high blood pressure standing out as the single strongest risk factor. Treatment has changed substantially over the past fifteen years, with injections of anti-VEGF drugs into the eye now serving as the frontline approach to preserve and often improve vision.

How a Clot Forms in the Central Retinal Vein

The central retinal vein exits the eye through a narrow channel in the optic nerve called the lamina cribrosa. This spot acts as a natural bottleneck. Blood velocities are measurably higher here than farther back in the optic nerve, suggesting the vein is physically squeezed as it passes through.¹ That constriction matters because it makes the vein vulnerable to the same trio of problems that cause clots elsewhere in the body: sluggish blood flow, damage to the vessel wall, and blood that clots too easily. This framework, originally described by Rudolf Virchow in the nineteenth century, applies directly to the retinal vein.² Anything that stiffens or thickens the neighboring retinal artery, which shares a tight connective-tissue sheath with the vein, can press on the vein and trigger clot formation at that bottleneck.

The Biggest Risk Factors

High blood pressure is far and away the most common systemic factor behind CRVO. A meta-analysis of published clinical data found that people with hypertension had roughly four times the odds of developing CRVO compared to those without it.³ Diabetes doubled the odds, and high cholesterol also showed a significant association. A separate large analysis found that people with all three components of metabolic syndrome (hypertension, diabetes, and high cholesterol together) had about a 58% increased risk of CRVO relative to those with none of those conditions, though hypertension alone accounted for a 66% increase.⁴ The practical takeaway is that CRVO is, in many cases, a vascular event with the same underlying drivers as heart attack and stroke.

Elevated pressure inside the eye also plays a role, though the relationship is more nuanced than it first appears. A Mendelian randomization study found that each 1 mmHg increase in intraocular pressure raised the odds of retinal vein occlusion by about 53%, but the analysis also showed that roughly 92% of that effect was funneled through primary open-angle glaucoma rather than acting independently.⁵ In other words, it is the glaucoma-related changes to the optic nerve head that seem to compress the vein, not just the elevated pressure by itself. A large Korean population study reinforced this bidirectional relationship, finding that CRVO patients were more likely to develop open-angle glaucoma afterward and vice versa.⁶

When It Happens in Younger People

CRVO is overwhelmingly a disease of older adults, but it does occur in people under fifty. When it does, the usual cardiovascular risk factors are often absent, and doctors look harder at blood-clotting disorders. A systematic review and meta-analysis across 95 studies found that inherited clotting mutations like Factor V Leiden appeared in about 6% of retinal vein occlusion patients, and the prothrombin gene mutation in about 3%.⁷ Antiphospholipid antibodies turned up in about 8%. Meanwhile, elevated homocysteine and high Factor VIII levels were strongly associated with CRVO in case-control studies.⁸

That said, the picture is far from tidy. A study of 50 patients under age fifty with retinal vein occlusion in North India found that classic thrombophilia markers like Factor V Leiden, Protein C deficiency, and Protein S deficiency were completely absent, and only a single patient had confirmed antiphospholipid syndrome.⁹ The researchers concluded that other, still poorly understood factors likely contribute in many young patients. For clinicians, this means a thrombophilia workup in a young patient with CRVO may or may not reveal a cause, but it is still worth doing because the handful of treatable conditions (like antiphospholipid syndrome) have implications beyond the eye.

What CRVO Does to Vision

The immediate threat to sight comes from macular edema, the swelling of the central retina caused by fluid leaking from damaged blood vessels. When the vein is blocked, pressure builds behind the clot, and the retinal vessels become leaky. The body responds by flooding the area with vascular endothelial growth factor (VEGF), a signaling molecule that makes vessels even more permeable. One study measuring VEGF levels in the vitreous fluid of CRVO patients found concentrations roughly 23 times higher than in healthy eyes, and the levels correlated with the severity of swelling.¹⁰ That same study found similarly elevated levels of an inflammatory adhesion molecule, pointing to an inflammatory component on top of the vascular one.

The other feared complication is neovascular glaucoma. When blood flow to large areas of the retina is cut off, the oxygen-starved tissue releases growth factors that stimulate abnormal new blood vessels on the iris and in the drainage angle of the eye, eventually blocking fluid outflow and sending eye pressure dangerously high. In a classic prospective study, about 20% of untreated CRVO eyes developed neovascular glaucoma, and the risk climbed to roughly 60% in eyes classified as severely ischemic.¹¹ This is why determining the degree of ischemia early on is so clinically important.

Ischemic Versus Non-Ischemic CRVO

Not all CRVOs behave the same way. Doctors classify them by how much blood flow the retina has lost. In the non-ischemic type, venous drainage is partially blocked but enough circulation remains to keep most retinal tissue alive. Vision tends to be less severely affected at the start, and many of these eyes avoid the worst complications. In the ischemic type, large swaths of the retina lose their blood supply, and the risk of neovascular glaucoma and profound vision loss is much higher.

The tricky part is that the categories are not fixed. A systematic review of the evidence found that up to 34% of non-ischemic CRVO eyes converted to the ischemic form within three years.¹² Predicting who will convert is difficult. A study tracking conversion rates found that older age and increasing retinal hemorrhages were strong warning signs for ischemic progression. Interestingly, how well a patient could read the eye chart at the time of diagnosis did not predict conversion.¹³ This is why regular follow-up visits in the months after diagnosis are essential, even when the initial presentation seems mild.

How Imaging Helps Guide Decisions

Optical coherence tomography angiography (OCT-A) has become a valuable tool for mapping exactly where blood flow has been lost. Unlike older fluorescein angiography, it does not require an injection of dye and can separately image the superficial and deep layers of retinal blood vessels. Studies using OCT-A in CRVO eyes have consistently shown that the deep vascular layer is more severely affected, with significantly reduced vessel density compared to healthy eyes.¹⁴ Even the choriocapillaris, the vascular layer beneath the retina, shows reduced flow in CRVO. The size of the areas without blood flow visible on OCT-A can also help predict which patients will have recurrent swelling after treatment.¹⁵

Anti-VEGF Injections

The standard first-line treatment for macular edema from CRVO is an injection of anti-VEGF medication directly into the eye. These drugs, including ranibizumab, aflibercept, and the newer faricimab, block the VEGF molecule responsible for vessel leakage and abnormal vessel growth. Real-world data on long-term results shows that CRVO eyes treated with anti-VEGF drugs improved from an average of about 52 letters on a standard vision chart to about 66 letters, a gain of roughly 14 letters, with retinal thickness dropping by about half.¹⁶ A separate observational study found that the initial vision gains of around 11-12 letters at six months held steady through the first year but drifted down to about a 7-letter gain by year five, suggesting some erosion of benefit over time.¹⁷

Most patients are treated with a “treat-and-extend” approach, where the interval between injections is gradually lengthened as long as the macula stays dry. Aflibercept tends to require fewer injections than ranibizumab under this protocol, which eases the burden of frequent clinic visits.¹⁸ Faricimab, which targets both VEGF and another pathway called Ang-2, is also being studied in a treat-and-extend format for CRVO, with the hope of further extending the time between injections.¹⁹ For patients, the practical reality of anti-VEGF treatment is an ongoing cycle of appointments and injections, sometimes over years. Missing follow-ups or stopping treatment too early is one of the most common reasons for vision to worsen again.

Steroid Implants as an Alternative

For patients who do not respond well to anti-VEGF injections, or who find the frequency of visits unsustainable, a dexamethasone intravitreal implant offers another option. This slow-release steroid pellet is injected into the eye and dissolves over several months, reducing both VEGF levels and the inflammatory component of the swelling. In a twelve-month trial, about 30-32% of patients achieved a meaningful vision improvement (15 or more letters) after each implant.²⁰ The implant also helped resolve swelling across all subtypes of CRVO, though eyes that already had significant damage to the outer retinal layers at baseline were less likely to see functional improvement.²¹

The trade-off is side effects. In the same twelve-month study, nearly 30% of patients with natural lenses experienced cataract progression after two implants, and about 12-15% developed a temporary spike in eye pressure that required medication.²⁰ Both of these side effects are manageable in most cases, but they make the steroid implant a less straightforward choice than anti-VEGF drugs for many patients, especially younger ones who want to avoid cataract surgery.

The Role of Laser Treatment

Before anti-VEGF drugs arrived, panretinal photocoagulation (PRP), a laser treatment that intentionally destroys peripheral retinal tissue to reduce VEGF production, was the main defense against neovascular glaucoma in ischemic CRVO. In a randomized trial, none of the treated patients progressed to neovascular glaucoma, and abnormal new vessels on the iris and disc regressed after laser.²² Earlier studies with laser also showed a lower rate of neovascular glaucoma compared to untreated ischemic eyes.²³

Today, the evidence favors careful monitoring rather than preventive laser. A major randomized trial from the Central Vein Occlusion Study found that prophylactic PRP did not fully prevent neovascularization, and that new vessels that appeared in previously untreated eyes actually responded better to laser than those that developed despite prophylactic treatment.²⁴ The current approach is therefore to watch ischemic eyes closely in the early months and apply PRP promptly if new vessels appear, rather than treating all ischemic eyes up front. Laser remains the treatment for neovascular complications specifically; it does not improve macular edema and is not used for that purpose in CRVO.²⁵

The Systemic Workup After Diagnosis

Because CRVO shares its risk factors with cardiovascular disease broadly, a diagnosis should prompt a workup beyond the eye. Blood pressure measurement, blood glucose testing, and a lipid panel are the minimum. Many patients with CRVO already have a history of cardiovascular disease, hypertension, or diabetes at the time of diagnosis. For younger patients or those without obvious cardiovascular risk factors, checking for clotting disorders, homocysteine levels, and inflammatory markers like antiphospholipid antibodies is standard practice. The point is not just to explain the CRVO but to catch systemic conditions that could cause problems elsewhere if left untreated.

Conditions That Can Mimic CRVO

A few conditions look enough like CRVO on initial examination to cause confusion. Ocular ischemic syndrome, which results from severe narrowing of the carotid artery rather than a clot in the retinal vein, can produce hemorrhages and swelling in the retina that overlap with CRVO on fundoscopic examination.²⁶ The distinction matters because ocular ischemic syndrome points to a life-threatening vascular problem in the neck or brain that demands urgent workup. Diabetic retinopathy can also mimic moderate CRVO, particularly when hemorrhages are widespread. A careful history, fluorescein angiography, and sometimes carotid imaging help sort these out.

How CRVO Affects Daily Life

Vision loss from CRVO goes beyond the eye chart. Research using a standardized questionnaire found that people with CRVO reported significantly lower scores on measures of vision-related quality of life, covering areas like reading, driving, recognizing faces, and overall emotional well-being.²⁷ Because CRVO typically strikes one eye, people retain functional vision from the unaffected side, but they lose depth perception and the comfortable peripheral coverage that two working eyes provide. Tasks that demand fine detail or quick visual reactions, like reading small print or judging distances while driving, become unreliable. The treatment burden compounds this: monthly or near-monthly clinic visits for injections, unpredictable flare-ups of swelling, and the anxiety of not knowing whether vision will hold steady or decline create a chronic stress that pure acuity measurements do not capture.